Stock CGON CG ONCOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus CG Oncology, Inc.

Equities

CGON

US1569441009

Real-time Estimate Cboe BZX
Other stock markets
 15:52:10 28/05/2024 BST 		5-day change 1st Jan Change
32.54 USD -0.52% Intraday chart for CG Oncology, Inc. +13.81% 0.00%
05-24 Sector Update: Health Care Stocks Softer in Friday Afternoon Trading MT
05-24 CG Oncology Shares Jump After Potential Combination Therapy for Bladder Cancer Meets Phase 2 Primary Endpoint MT

Evolution of the average Target Price on CG Oncology, Inc.

Price target over the last 5 years

History of analyst recommendation changes

1dc6c12805358546e.sMpiSgZPdxHvGs34QjGstdNYXJWwkJqxt5HZ-2LVJCA.2p1PC04qNSmoSKWwMFb8_JEzMc_q1fv_89vvihiPERT5nSU5Xj0iU4d-vg~e0eecff7fb9b67e2f61ca19b48dcd7c5

Analyst Recommendations on CG Oncology, Inc.

Goldman Sachs Upgrades CG Oncology to Buy From Neutral With $50 Price Target MT
Cantor Fitzgerald Starts Coverage on CG Oncology With Overweight Rating, $75 Price Target MT
Goldman Sachs Initiates Coverage on CG Oncology With Neutral Rating, $42 Price Target MT
Morgan Stanley Initiates CG Oncology With Overweight Rating, Price Target is $55 MT
HC Wainwright Starts Coverage on CG Oncology With Buy Rating, $75 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
32.71 USD
Average target price
68.2 USD
Spread / Average Target
+108.50%
High Price Target
86 USD
Spread / Highest target
+162.92%
Low Price Target
50 USD
Spread / Lowest Target
+52.86%

Consensus detail

Consensus revision (last 18 months)

Analysts covering CG Oncology, Inc.

Goldman Sachs
Cantor Fitzgerald
Morgan Stanley
HC Wainwright

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CGON Stock
  4. Consensus CG Oncology, Inc.